Golden Green’s Regeneron Pharmaceuticals REGN Stock Holding History

Golden Green’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-437	Closed	-$244K	–	167
2021 Q2	$244K	Buy	+437	New	+$221K	0.19%	133

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Golden Green's REGN Position: Q3 2021 in Review

Golden Green sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 437 shares — an estimated $244K sold.

Golden Green first reported a position in REGN in Q2 2021 and held it in 1 quarter. The position peaked at $244K in Q2 2021. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

Golden Green reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Golden Green sold 437 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $244K.
Golden Green first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Golden Green's Regeneron Pharmaceuticals position peaked at $244K in Q2 2021.
1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Golden Green's 13F filing for Q3 2021, filed 8 Oct 2021.